Projects
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of an Oral Factor XIa Inhibitor, after a Recent Acute Coronary Syndrome (Milvexian ACS)
Project Description
Description: The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
Project Duration
2023 - Ongoing
Project Lead
Dr. Denis Xavier
Authors
Dr. Denis Xavier
Project Status
ongoing